Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by IlluminaBusiness Wire • 03/17/22
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual MeetingBusiness Wire • 03/09/22
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 OutlookBusiness Wire • 02/23/22
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022Business Wire • 02/01/22
After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)Zacks Investment Research • 01/20/22
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers SymposiumBusiness Wire • 01/19/22
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk AdultsBusiness Wire • 01/18/22
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology LitigationBusiness Wire • 01/07/22
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/29/21
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal CancerBusiness Wire • 12/17/21
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer SymposiumBusiness Wire • 12/06/21
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal CancerBusiness Wire • 11/11/21
Guardant Health Registers 27% Revenue Growth In Q3, Tops Consensus; Backs FY21 GuidanceBenzinga • 11/05/21
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21